Used primarily in research related to obesity and metabolic disorders, the compound acts as a selective blocker of cannabinoid receptors, particularly CB1. This action helps reduce appetite and food intake, leading to weight loss. It has been investigated for managing conditions like type 2 diabetes and dyslipidemia due to its effects on improving insulin sensitivity and lipid profiles. Additionally, studies have explored its potential in treating substance use disorders, including nicotine dependence, by modulating reward pathways in the brain. However, its use is limited due to psychiatric side effects, and it remains a tool for scientific study rather than clinical therapy.